Home / Expertise / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

Slovenia

With over 150 international specialist lawyers across CMS and the support of the Life Sciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your life sciences & healthcare business. We work with and have established long-term relationships with the top 100 life sciences & healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations we help shape the legal frameworks impacting the life sciences & healthcare sector.

We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice and compliance. Equally, when you need life sciences & healthcare specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less

Feed

Show only
1 July 2020
Sign­ing with e-sig­na­ture in CEE
Di­git­al­isa­tion af­fects all as­pects of a busi­ness’s op­er­a­tions, in­clud­ing con­tracts, in­tern­al doc­u­ment­a­tion and em­ploy­ment re­la­tion­ships. The COV­ID-19 pan­dem­ic has cre­ated the need for con­tact­less and...
14 December 2020
CMS Ex­pert Guide to di­git­al health apps and telemedi­cine
Fu­ture fa­cing Di­git­isa­tion is ad­van­cing stead­ily. Its pi­on­eer­ing in­nov­a­tions chal­lenge all parties in­volved. One of the most im­port­ant as­pects in this area is the huge po­ten­tial that lies in the di­git­isa­tion...
Comparable
13 January 2021
EU­'s Por­tuguese pres­id­ency re­leases new draft of ePri­vacy Reg­u­la­tion
On 5 Janu­ary 2021, the Coun­cil of the EU – with Por­tugal serving as the Pres­id­ent-in-Of­fice – re­leased a new draft ver­sion of the ePri­vacy Reg­u­la­tion, which is meant to re­place the ePri­vacy Dir­ect­ive...
25 June 2019
AI in Life Sci­ences
At CMS, we have many law­yers in many coun­tries think­ing about the in­creas­ing im­pact of AI on the life sci­ences leg­al land­scape. Rather than keep these thoughts to ourselves, we thought we would share...
20 April 2020
CMS Ex­pert Guide to ad­vert­ising of medi­cines and med­ic­al devices
Ad­vert­ising of phar­ma­ceut­ic­als and med­ic­al devices is a chal­len­ging area for the Life Sci­ences and Health­care in­dustry.The leg­al frame­work is con­stantly chan­ging. Due to very few laws on this area, there...
16 December 2020
EU Com­mis­sion pub­lishes pro­posed Data Gov­ernance Reg­u­la­tion
On 25 Novem­ber 2020 the European Com­mis­sion pro­posed new rules on data gov­ernance – a pro­posed Data Gov­ernance Reg­u­la­tion, which is the first of a set of meas­ures an­nounced in the 2020 European strategy...
01/01/2018
Good medi­cine in­stead of bit­ter pills
Leg­al ques­tions re­gard­ing health­care also play an im­port­ant role in times of eco­nom­ic change. We ad­vise nu­mer­ous dis­tin­guished cli­ents, such as es­tab­lished health­care fa­cil­it­ies in or­der for them to ful­fil...
20 April 2020
CMS Ex­pert Guide to can­nabis law and le­gis­la­tion
In re­cent years can­nabis trade and re­lated activ­ity has de­veloped in­to a growth busi­ness area. In the life sci­ences and health­care fields there have been in­creases in the num­bers of pa­tients hav­ing ac­cess...
15 December 2020
Five years after Hua­wei ZTE FRAND li­cens­ing ob­lig­a­tions again be­fore the...
On 26 Novem­ber 2020, the Düs­sel­dorf Re­gion­al Court an­nounced that it would sus­pend a pat­ent in­fringe­ment pro­ceed­ing and refer key ques­tions on com­puls­ory li­cens­ing of stand­ard es­sen­tial pat­ents (SEP)...
15/12/2015
CMS Glob­al Lifes­ci­ences For­um 2015
On 9 Novem­ber 2015, Lifes­ci­ences pro­fes­sion­als from around the world gathered to dis­cuss the in­dustry’s hot­test top­ics at the CMS Glob­al Lifes­ci­ences For­um 2015. In this re­port, we sum­mar­ise the chal­lenges...
03 December 2020
With the in­tro­duc­tion of a new Phar­ma­ceut­ic­al Strategy for Europe, the...
New Phar­ma­ceut­ic­al Strategy to be a corner­stone of the European Health Uni­on The new Phar­ma­ceut­ic­al Strategy for Europe, an­nounced by the EU Com­mis­sion on 25 Novem­ber, is ex­pec­ted to be­come a main pil­lar...
19/02/2015
Un­der the Mi­cro­scope
'Un­der the Mi­cro­scope' takes a look back at some of the key leg­al de­vel­op­ments in the Lifes­ci­ences sec­tor in 2014 across Europe, in­clud­ing:Reg­u­lat­ory/Com­pet­i­tion­Com­pli­ance/Trans­par­ency­In­tel­lec­tu­al Prop­er­tyProduct...